Funding for this research was provided by:
Received: 27 January 2022
Accepted: 3 March 2022
First Online: 19 March 2022
: The present study is a pooled analysis of previously collected and/or published data; informed consent was already provided by patients. The pooled analysis of the ESTEEMen study was approved by the Internal Review Board of the University of L’Aquila with protocol number 07/2021; approval was shared with all the study centers. Local ethical approval to pool data was obtained if needed.
: Not applicable.
: RO reports personal fees from Novartis, Teva, and Eli Lilly, and had non-financial relationships with Allergan/AbbVie, Novartis and Teva. SS reports personal fees and nonfinancial support from Allergan, Abbott, Eli Lilly, Novartis, and Teva; personal fees from Medscape; and other from Bayer, Pfizer, Medtronic, Starmed, Bristol-Myers Squibb, and Daiichi Sankyo. BR reports research grants from Novartis, and personal fees from Allergan, Lilly, Novartis, and Teva. UR received honoraria for consulting and lectures from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva, and research funding from the German Federal Ministry of Education and Research and Novartis. GAf reports competing interests with Novartis. MAG reports competing interests with Helsinn Healthcare and Uriach Italy. GL has received speaker honoraria, funding for travel, and honoraria for participation in advisory boards sponsored by Allergan, TEVA, Lilly and Novartis; he has received speaker honoraria and funding for travel from electroCore, Nevro Corp, and Autonomic Technologies. NL reports personal fees from Novartis and Allergan. EА reports personal fees from Novartis and Teva. CB and SG received honoraria from Allergan, Teva, Eli Lilly and Novartis. DH reports personal fees from Novartis, Teva, Eli Lilly, Allergan, Hormosan, Zuellig Pharma, Bayer. AR received speaker honoraria from Novartis, Teva, and Eli Lilly. SCe received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, Amgen and Lundbeck. VF has received honoraria as speaker or for participating in advisory boards from Eli Lilly, Novartis and Teva. AR has received speaker honoraria from Allergan, Lilly, Novartis and Teva. MSi has received speaker honoraria from Lilly, Novartis and Teva. FV received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan, Eli-Lilly, Novartis, and Teva. PB received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Alder, Allergan, Bayer, ElectroCore, Eli-Lilly, GSK, Lusofarmaco, MSD, Novartis, Stx-Med, Teva, and Visufarma. CA received travel grants from Eli-Lilly, FB-Health, Lusofarmaco, and Teva. MF, AG, SC, JT, TN, DČ, JŠ, ZM, LS, AS, MM, GAl, EDV, AM, AC, SV, CA, and FP report no conflict of interest.